Acute hepatitis C: management in the rapidly evolving world of HCV

Suraj A Sharma1, Jordan J Feld

  • 1Toronto Center for Liver Disease, Sandra Rotman Centre for Global Health, University Health Network, University of Toronto, 6B-Fell Pavilion, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada.

Insights

Recognizing acute hepatitis C virus (HCV) infection is crucial for timely treatment, as many patients are asymptomatic. Early intervention improves outcomes and prevents chronic liver disease.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection's acute phase is typically 6 months but can extend.
  • Most acute HCV infections are asymptomatic, delaying diagnosis until chronic disease develops.
  • HCV can lead to decompensated cirrhosis or hepatocellular carcinoma (HCC) decades after initial infection.

Purpose of the Study:

  • To review the epidemiology, natural history, diagnosis, and treatment of acute HCV infection.
  • To highlight the importance of identifying acute HCV for effective treatment.
  • To discuss the potential impact of new all-oral therapies on acute HCV management.

Main Methods:

  • Literature review focusing on acute hepatitis C.
  • Analysis of epidemiological data and natural history studies.
  • Evaluation of diagnostic and treatment strategies for acute HCV.

Main Results:

  • A significant proportion (20-40%) of patients spontaneously clear HCV during the acute phase.
  • Interferon-based treatment is more effective in the acute phase but poorly tolerated.
  • Delayed diagnosis is common due to asymptomatic presentation.

Conclusions:

  • Early recognition of acute HCV is critical for initiating therapy in non-clearing patients.
  • Emerging all-oral therapies may change the management paradigm for acute HCV.
  • Further research is needed to optimize diagnosis and treatment strategies for acute HCV infection.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657